Bristol Continues R&D Outsourcing: GSK VP Palmer Named CSO
Executive Summary
Bristol-Myers Squibb Chief Scientific Officer-designate James Palmer, MD, brings 15 years of experience in clinical development at Glaxo and its successor companies
You may also be interested in...
GSK senior VP-worldwide development
AstraZeneca Senior VP-U.S. Drug Development Ronald Krall, MD, joins GlaxoSmithKline as senior VP-worldwide development, research & development, effective Feb. 19. Krall succeeds James Palmer, MD, who served as senior VP-new product development and left GSK in October to become Bristol Myers-Squibb chief scientific officer (1"The Pink Sheet" Oct. 28, 2002, p. 15). AstraZeneca VP-Clinical Development Glenn Gormley, MD, is succeeding Krall on an acting basis....
GSK senior VP-worldwide development
AstraZeneca Senior VP-U.S. Drug Development Ronald Krall, MD, joins GlaxoSmithKline as senior VP-worldwide development, research & development, effective Feb. 19. Krall succeeds James Palmer, MD, who served as senior VP-new product development and left GSK in October to become Bristol Myers-Squibb chief scientific officer (1"The Pink Sheet" Oct. 28, 2002, p. 15). AstraZeneca VP-Clinical Development Glenn Gormley, MD, is succeeding Krall on an acting basis....
GSK Avandamet Antidiabetic Combo Expected In Pharmacies In November
GlaxoSmithKline's Avandamet combination rosiglitazone/metformin product for diabetes is expected to be available in November, the company said after Oct. 10 FDA approval